New Sights in Vaccines and Immunotherapy for Liver Cancer
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 432
Special Issue Editor
Interests: hepatocellular carcinoma; cholangiocellular carcinoma; mini invasive interventional oncology treatments
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Liver cancer is a major health problem, with more than 850,000 new cases annually worldwide. This neoplasm is currently the second leading cause of cancer-related death globally. Among all primary liver cancers, hepatocellular carcinoma (HCC) is the most common neoplasm, accounting for approximately 90% of cases. Treatments that have been shown to extend patients' life expectancy with HCC include surgical resection, liver transplantation, radiofrequency ablation, chemoembolization, and the multi-kinase inhibitor sorafenib. Curative treatments are possible in around 40% of patients, usually in the early and very early stages, through surgical (resection and transplantation) and percutaneous (radiofrequency or microwaves) techniques. Patients with more advanced disease still restricted to the liver usually receive trans-arterial therapies, including chemoembolization and radioembolization, which are considered not curative treatments. In contrast, patients without this possibility and with metastatic disease should undergo medical treatments.
The recent discoveries of new molecular mechanisms of tumor maintenance have allowed advancement in the therapy of this type of cancer. Immunotherapy represents a new frontier in this scenario. Simultaneously, local treatments inducing tumor necrosis and/or massive apoptosis offer an opportunity to be combined with immunotherapy approaches.
This Special Issue focuses on cancer vaccines and immunotherapy research. Besides, Papers concerning the standard of care and the new emergent therapies, and how they can be combined in Liver Cancers are also welcome.
Dr. Gianpaolo Vidili
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Liver Cancer
- hepatocellular and cholangiocellular carcinoma
- hepatic lymphoma
- vaccines
- Immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
